 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- NST-628 / Nested Therap
A Phase 1, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations. (Hall 6 - Poster area) - Jul 24, 2024 - Abstract #ESMO2024ESMO_3700;
- ||| NST-628 / Nested Therap
Enrollment open: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors (clinicaltrials.gov) - Mar 27, 2024
P1, N=230, Recruiting, Sponsor: Nested Therapeutics, Inc
Not yet recruiting --> Recruiting
- | NST-628 / Nested Therap
New P1 trial: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors (clinicaltrials.gov) - Mar 22, 2024
P1, N=230, Not yet recruiting, Sponsor: Nested Therapeutics, Inc
- NST-628 / Nested Therap
NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers (Ballroom 20 CD - Upper Level - Convention Center) - Mar 17, 2024 - Abstract #AACR2024AACR_9981;
Not yet recruiting --> Recruiting Abstract is embargoed at this time.
- NST-628 / Nested Therap, roniciclib (BAY1000394) / Bayer, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Target identification, selectivity profiling and binding site mapping of small molecule and peptide drugs by LiP-MS (Section 21) - Mar 5, 2024 - Abstract #AACR2024AACR_7637;
Nature Comm 2020 [2] Hendricks and Beaton et al. ACS Chem Bio 2021 [3] AACR 2022 [4] AACR 2023 [5] AACR-NCI-EORTC 2023
- NST-628 is a potent, fully brain-penetrant, RAS/MAPK pathway molecular glue inhibitor with efficacy in CNS tumor models. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_244;
- NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS- and RAFdriven cancers. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_243;
- NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_241;